<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Interv Aging</journal-id>
      <journal-title-group>
        <journal-title>Clinical Interventions in Aging</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1176-9092</issn>
      <issn pub-type="epub">1178-1998</issn>
      <publisher>
        <publisher-name>Dove Medical Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19851514</article-id>
      <article-id pub-id-type="pmc">2762363</article-id>
      <article-id pub-id-type="publisher-id">cia-4-391</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Yanai</surname>
            <given-names>Hidekatsu</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cia-4-391">1</xref>
          <xref ref-type="aff" rid="af2-cia-4-391">2</xref>
          <xref ref-type="corresp" rid="c1-cia-4-391"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yoshida</surname>
            <given-names>Hiroshi</given-names>
          </name>
          <xref ref-type="aff" rid="af2-cia-4-391">2</xref>
          <xref ref-type="aff" rid="af3-cia-4-391">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tada</surname>
            <given-names>Norio</given-names>
          </name>
          <xref ref-type="aff" rid="af1-cia-4-391">1</xref>
          <xref ref-type="aff" rid="af2-cia-4-391">2</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-cia-4-391"><label>1</label> Division of General Medicine, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan</aff>
      <aff id="af2-cia-4-391"><label>2</label> Institute of Clinical Medicine and Research, the Jikei University School of Medicine, Chiba, Japan</aff>
      <aff id="af3-cia-4-391"><label>3</label> Department of Laboratory Medicine, The Jikei University School of Medicine, Kashiwa, Japan</aff>
      <author-notes>
        <corresp id="c1-cia-4-391">Correspondence: Hidekatsu Yanai, Division of General Medicine, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa, Japan, Tel +81 4 7164 1111, Fax +81 4 7164 1126, Email
<email>yanaih@jikei.ac.jp</email></corresp>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2009</year>
      </pub-date>
      <!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub-->
      <pub-date pub-type="ppub">
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>10</month>
        <year>2009</year>
      </pub-date>
      <volume>4</volume>
      <fpage>391</fpage>
      <lpage>395</lpage>
      <permissions>
        <copyright-statement>&#xA9; Yanai et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement>
        <license>
          <license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>To find out clues to differentiate between polymyalgia rheumatica (PMR) and other diseases that mimic PMR. We studied Japanese patients with PMR (n = 7), pseudogout (n = 1), remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome (n = 1), and post-infectious polyarthritis (n = 1). The distribution of inflammation in patients was evaluated using a gallium-67 scintigraphy. We measured serum C-reactive protein (CRP), matrix metalloproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF) in patients before and after treatment. Further, we compared the clinical course of PMR with that of other diseases that mimic PMR. Patients with pseudogout, RS3PE syndrome, post-infectious polyarthritis manifested similar changes in scintigraphic findings and serum CRP, MMP-3, and VEGF levels to PMR before the treatment. A significant reduction in serum CRP levels at one week after use of nonsteroidal anti-inflammatory drugs (NSAIDs) is a good clue to differentiate pseudogout and post-infectious polyarthritis from PMR. Chondrocalcinosis in the radiographs of joints is also effective to differentiate pseudogout from PMR. A small reduction of CRP levels after NSAIDs use and promptly ameliorated CRP and symptoms by a low-dose steroid therapy, which was commonly observed in patients with PMR, were also found in a patient with RS3PE syndrome. Pitting edema of the back of hands and gallium uptake in metacarpophalangeal (MCP) joints were useful to differentiate RS3PE syndrome from PMR. In conclusion, pseudogout, RS3PE syndrome, post-infectious polyarthritis should be included in the spectrum of diseases mimicking PMR. A promptly decreased serum CRP level by NSAIDs is a good clue to differentiate pseudogout and post-infectious polyarthritis from PMR. Pitting edema of the back of hands and symmetric gallium uptake in MCP joints are characteristic for RS3PE syndrome.</p>
      </abstract>
      <kwd-group>
        <kwd>gallium-67 scintigraphy</kwd>
        <kwd>polymyalgia rheumatica</kwd>
        <kwd>pseudogout</kwd>
        <kwd>post-infectious polyarthritis</kwd>
        <kwd>RS3PE syndrome</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease in elderly people. It is a common indication for a long term treatment with steroid in patients based in the community. Although the cause of PMR is largely unknown, the presence of articular synovitis in PMR has been proven by synovial biopsy.<xref ref-type="bibr" rid="b1-cia-4-391">1</xref> Recently, we have reported that symmetrical gallium-67 uptake in the shoulders and elevated serum matrix metal-loproteinase-3 (MMP-3) and vascular endothelial growth factor (VEGF) levels as the markers for synovitis in patients with PMR.<xref ref-type="bibr" rid="b2-cia-4-391">2</xref> Although bilateral aching and stiffness of shoulders and pelvic girdle of acute or subacute onset are very characteristic for PMR, several other diseases can be present with similar symptoms. Here, we studied a gallium scintigraphic findings, and serum C-reactive protein (CRP), MMP-3 and VEGF levels in patients with diseases that mimic PMR. Further, we discuss clues to differentiate between PMR and other diseases that mimic PMR.</p>
    </sec>
    <sec sec-type="methods">
      <title>Methods</title>
      <p>We studied Japanese patients with PMR (n = 7), pseudogout (n = 1), remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome (n = 1), and post-infectious polyarthritis (n = 1). Diagnosis for PMR had been done using the Hunder&#x2019;s criteria.<xref ref-type="bibr" rid="b3-cia-4-391">3</xref> The distribution of inflammation in patients was evaluated using a gallium-67 scintigraphy whole body scan before the treatment. We measured serum CRP, MMP-3, and VEGF levels as the markers for a synovial inflammation before and after the treatment.<xref ref-type="bibr" rid="b4-cia-4-391">4</xref>,<xref ref-type="bibr" rid="b5-cia-4-391">5</xref> Serum CRP and MMP-3 concentrations were measured by polyclonal antibody-based (Dade Behring, Marburg, Germany) and monoclonal antibody-based (Daiichi Fine Chemical, Co., Ltd., Toyama, Japan) latex agglutination method, respectively. Serum concentrations of VEGF<sub>165</sub> (major form of VEGF) were analyzed by enzyme linked immunosorbent assay (ELISA; VEGF<sub>165</sub>, R&amp;D Systems, Inc, Minneapolis, MN, USA).</p>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <sec sec-type="subjects">
        <title>Patients with PMR</title>
        <p>Case P is a 64-year-old woman with PMR (<xref ref-type="fig" rid="f1-cia-4-391">Figure 1P</xref>). Symmetrical and bilateral gallium uptake in shoulders, pelvic girdle, and knees were observed. Age of all patients with PMR were over 50 years (<xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>). Serum CRP (normal range, &lt;0.3 mg/dL), MMP-3 (normal range, &lt;115 ng/ml), and VEGF (normal range, 17.3&#x2013;59.7 pg/ml) levels were significantly elevated in patients with PMR before the treatment (<xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>). Rheumatic factor (RF), antinuclear antibody (ANA), myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA), and proteinase-3 (PR3)-ANCA were negative in all PMR patients. Daily administration of 20 mg corticosteroid ameliorated symptoms and significantly decreased serum CRP and VEGF levels (<xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>). Although a statistically significant difference between values before and after the treatment was not observed, corticosteroid increased serum MMP-3 levels. Nonsteroidal anti-inflammatory drugs (NSAIDs) did not ameliorate patients&#x2019; symptoms and serum CRP levels (<xref ref-type="table" rid="t2-cia-4-391">Table 2</xref>).</p>
      </sec>
      <sec>
        <title>Case A</title>
        <p>An 83-year-old man was admitted via emergency room complaining of fever and polyarthralgia, including bilateral wrists, knees, and hip joints. His body temperature was 38.1 &#xB0;C. Physical examination showed swelling of wrists, knees, and hip joints. Laboratory evaluation on admission was notable for a CRP level of 24.3 mg/dl, and RF, ANA, MPO-ANCA, and PR3-ANCA were negative. Serum MMP-3 and VEGF levels were elevated before the treatment (<xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>). His clinical and biochemical characteristics, and symmetrical and bilateral gallium uptake in shoulders, pelvic girdle, knees, and ankles, suggested the presence of PMR (<xref ref-type="fig" rid="f1-cia-4-391">Figure 1A</xref>). However, the radiographs of the wrist (<xref ref-type="fig" rid="f2-cia-4-391">Figure 2A</xref>), knee (<xref ref-type="fig" rid="f2-cia-4-391">Figure 2B</xref>), and hip (<xref ref-type="fig" rid="f2-cia-4-391">Figure 2C</xref>) showed chondrocalcinosis. Arthrocentesis on the right knee was performed. Calcium pyrophosphate dihydrate crystals were detected in the joint fluid, suggesting that this patient was having pseudogout. Loxoprofen (180 mg/day), NSAIDs, promptly ameliorated his symptoms and decreased serum CRP level (1.2 mg/dl at seven days after the treatment started) (<xref ref-type="table" rid="t2-cia-4-391">Table 2</xref>), and also decreased serum MMP-3 and VEGF levels.</p>
      </sec>
      <sec>
        <title>Case B</title>
        <p>A 65-year-old man was diagnosed as having deep venous thrombosis (DVT) because of edema and pain in lower extremities by a family physician, and was referred to the department of cardiology. The cardiologist found no evidence of DVT and elevated serum CRP level, and then this patient was referred and admitted to our department. He complained of fever, polyarthralgia, and pitting edema in bilateral hands and legs. A gallium-67 scintigraphy revealed symmetrical uptake in shoulders, elbows, wrists, pelvic girdle, knees, and ankles (<xref ref-type="fig" rid="f1-cia-4-391">Figure 1B</xref>). In contrast to PMR, a symmetrical gallium uptake in MCP joints was observed. Serum MMP-3 and VEGF levels were significantly elevated (<xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>), and RF, ANA, MPO-ANCA, and PR3-ANCA were negative. He was finally diagnosed as having RS3PE syndrome. NSAIDs did not ameliorate patient&#x2019;s symptoms and serum CRP, however, a low dose of steroid (daily use of 20 mg prednisolone) was very effective in relieving his symptoms and decreasing serum CRP level. Pitting edema on the back of hands and symmetric gallium uptake in MCP joints are characteristic for RS3PE syndrome.</p>
      </sec>
      <sec>
        <title>Case C</title>
        <p>An 89-year-old woman was admitted to the department of ophthalmology due to left intraocular inflammation, and her left eyeball was extracted. At the fourth day after eyeball extraction, she had fever (39.2 &#xB0;C), and her serum CRP level was elevated (14.5 mg/dl). Antibiotic therapy was started, but, antibiotic did not decrease her body temperature and serum CRP level (12.1 mg/dl at the fifth day after the beginning of antibiotic therapy), and she was referred and admitted to our department. She complained of fever and polyarthralgia. Serum RF, ANA, MPO-ANCA, and PR3-ANCA were negative. Symmetrical gallium uptake in shoulders, elbows, wrists, knees, and ankles in a gallium-67 scintigraphy (<xref ref-type="fig" rid="f1-cia-4-391">Figure 1C</xref>) and elevated serum MMP-3 and VEGF levels (<xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>) suggested the presence of PMR. We stopped use of antibiotics and started to use loxoprofen (60&#x2013;120 mg/day), NSAIDs. Loxoprofen promptly ameliorated her symptoms and decreased serum CRP level (1.3 mg/dl at the seventh day after the treatment started). Her clinical course suggested that she was having post-infectious polyarthritis due to intraocular inflammation.</p>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>PMR is a common disease in the elderly. In the United Kingdom, age-adjusted incidence of diagnosed PMR was reported to have increased by 35% between 1990 and 2001.<xref ref-type="bibr" rid="b6-cia-4-391">6</xref> However, it is not clear whether this suggests a true increase, increased recognition, or overdiagnosis of PMR. There is considerable uncertainty related to diagnosis in patients with PMR.<xref ref-type="bibr" rid="b7-cia-4-391">7</xref></p>
      <p>Recently, developing classification criteria for PMR has been reported.<xref ref-type="bibr" rid="b8-cia-4-391">8</xref> Most survey respondents agreed on the importance of seven core criteria. These were 1) age &#x2265; 50 years, 2) duration &#x2265;2 weeks, 3) bilateral shoulder and/or pelvic girdle aching, 4) duration of morning stiffness &gt;45 min, 5) elevated erythrocyte sedimentation rate, 6) elevated CRP, and 7) rapid steroid response. All other core criteria except rapid steroid response were observed in patients with pseudogout and post-infectious polyarthritis, and all core criteria were observed in a patient with RS3PE syndrome, suggesting that this newly developed classification cannot distinguish pseudogout, post-infectious polyarthritis, and RS3PE syndrome from PMR.</p>
      <p>Clinical and biochemical characteristics for PMR that we newly found were shown in <xref ref-type="table" rid="t3-cia-4-391">Table 3</xref>. Patients with pseudogout, RS3PE syndrome, post-infectious polyarthritis manifested similar changes in scintigraphic findings and serum CRP, MMP-3, and VEGF to PMR. A good response to NSAIDs is an effective clue to differentiate pseudogout and post-infectious polyarthritis from PMR.<xref ref-type="bibr" rid="b9-cia-4-391">9</xref>,<xref ref-type="bibr" rid="b10-cia-4-391">10</xref> An abnormality (chondrocalcinosis) in the radiographs of joints is also effective to differentiate pseudogout from PMR. Serum CRP level (24.3 mg/dl) in our patient (Case A) with pseudogout was quite high. A Korean female patient of calcium pyrophosphate dihydrate crystal deposition disease (CPDD) presenting as an acute polyarthritis also showed significantly elevated serum CRP levels (18.8 mg/dl).<xref ref-type="bibr" rid="b11-cia-4-391">11</xref> However, it is too difficult to differentiate CPDD and CPDD + PMR from PMR, especially in elderly patients.<xref ref-type="bibr" rid="b12-cia-4-391">12</xref> Therefore, we cannot completely deny a possible existence of an additional inflammatory condition including PMR in Case A.</p>
      <p>A significant difference in gallium scintigraphic findings in RS3PE syndrome as compared with PMR was the presence of gallium uptake in both MCP joints. However, symmetrical gallium uptake was observed in shoulders and pelvic girdle, showing the similar scintigraphic findings to PMR. RS3PE syndrome is a very rare inflammatory arthritis.<xref ref-type="bibr" rid="b13-cia-4-391">13</xref> The features of this syndrome are bilateral pitting edema of both hands, sudden onset of polyarthritis, age &gt; 50 years old, seronegative for RF.<xref ref-type="bibr" rid="b14-cia-4-391">14</xref> Mild to moderate synovitis of the joints and an association of VEGF with the pathogenesis have been observed in RS3PE syndrome as well as PMR.<xref ref-type="bibr" rid="b5-cia-4-391">5</xref>,<xref ref-type="bibr" rid="b15-cia-4-391">15</xref>,<xref ref-type="bibr" rid="b16-cia-4-391">16</xref> Elevated serum CRP, MMP-3 and VEGF levels, a bad response to NSAIDs, and rapid steroid response, were observed in our patient with RS3PE syndrome as well as patients with PMR. Pitting edema of the back of hands and symmetric gallium uptake in MCP joints are characteristic for RS3PE syndrome. As neoplasm are common in RS3PE syndrome, but not in PMR. Follow-up evaluation has been suggested to be necessary to observe for the possible occurrence of associated neoplasms.<xref ref-type="bibr" rid="b17-cia-4-391">17</xref></p>
      <p>In conclusion, pseudogout, RS3PE syndrome, post-infectious polyarthritis should be included in the spectrum of diseases mimicking PMR. A good response to NSAIDs is a good clue to differentiate pseudogout and post-infectious polyarthritis from PMR. Pitting edema of the back of hands and symmetric gallium uptake in MCP joints are characteristic for RS3PE syndrome.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Disclosures</bold>
        </p>
        <p>The authors report no conflicts of interest in this work.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="b1-cia-4-391">
        <label>1</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salvarani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hunder</surname>
              <given-names>GG</given-names>
            </name>
          </person-group>
          <article-title>Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis</article-title>
          <source>Arthritis Rheum</source>
          <year>1999</year>
          <volume>42</volume>
          <fpage>1259</fpage>
          <lpage>1266</lpage>
          <pub-id pub-id-type="pmid">10366120</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b2-cia-4-391">
        <label>2</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yanai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Furutani</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yoshida</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tada</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Scintigraphic findings and serum matrix metalloproteinase 3 and vascular endothelial growth factor levels in patients with polymyalgia rheumatica</article-title>
          <source>The Open General and Internal Medicine Journal</source>
          <year>2009</year>
          <volume>3</volume>
          <fpage>53</fpage>
          <lpage>57</lpage>
        </mixed-citation>
      </ref>
      <ref id="b3-cia-4-391">
        <label>3</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chuang</surname>
              <given-names>TY</given-names>
            </name>
            <name>
              <surname>Hunder</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Ilstrup</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Kurland</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
          <article-title>Polymyalgia rheumatica: a 10-year epidemiologic and clinical study</article-title>
          <source>Ann Intern Med</source>
          <year>1982</year>
          <volume>97</volume>
          <fpage>672</fpage>
          <lpage>680</lpage>
          <pub-id pub-id-type="pmid">6982645</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b4-cia-4-391">
        <label>4</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ribbens</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Martin y Porras</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Franchimont</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment</article-title>
          <source>Ann Rheum Dis</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>161</fpage>
          <lpage>166</lpage>
          <pub-id pub-id-type="pmid">11796404</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b5-cia-4-391">
        <label>5</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meliconi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pulsatelli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dolzani</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vascular endothelial growth factor production in polymyalgia rheumatica</article-title>
          <source>Arthritis Rheum</source>
          <year>2000</year>
          <volume>43</volume>
          <fpage>2472</fpage>
          <lpage>2480</lpage>
          <pub-id pub-id-type="pmid">11083270</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b6-cia-4-391">
        <label>6</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smeeth</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990&#x2013;200</article-title>
          <source>Ann Rheum Dis</source>
          <year>2006</year>
          <volume>65</volume>
          <fpage>1093</fpage>
          <lpage>1098</lpage>
          <pub-id pub-id-type="pmid">16414971</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b7-cia-4-391">
        <label>7</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dasgupta</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hutchings</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Matteson</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Polymyalgia rheumatica: the mess we are now in and what we need to do about it</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>55</volume>
          <fpage>518</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="pmid">16874793</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b8-cia-4-391">
        <label>8</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dasgupta</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Salvarani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schirmer</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey</article-title>
          <source>J Rheumatol</source>
          <year>2008</year>
          <volume>35</volume>
          <fpage>270</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="pmid">18050370</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b9-cia-4-391">
        <label>9</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petersel</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Sigal</surname>
              <given-names>LH</given-names>
            </name>
          </person-group>
          <article-title>Reactive arthritis</article-title>
          <source>Infect Dis Clin North Am</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>863</fpage>
          <lpage>883</lpage>
          <pub-id pub-id-type="pmid">16297737</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b10-cia-4-391">
        <label>10</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Announ</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Guerne</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Treating difficult crystal pyrophosphate dihydrate deposition disease</article-title>
          <source>Curr Rheumatol Rep</source>
          <year>2008</year>
          <volume>10</volume>
          <fpage>228</fpage>
          <lpage>234</lpage>
          <pub-id pub-id-type="pmid">18638432</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b11-cia-4-391">
        <label>11</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Song</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>A case of calcium pyrophosphate dihydrate crystal deposition disease presenting as an acute polyarthritis</article-title>
          <source>J Korean Med Sci</source>
          <year>2002</year>
          <volume>17</volume>
          <fpage>423</fpage>
          <lpage>425</lpage>
          <pub-id pub-id-type="pmid">12068153</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b12-cia-4-391">
        <label>12</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pego-Reigosa</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Rodriguez-Rodriguez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hurtado-Hernandez</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms</article-title>
          <source>Arthritis Rheum</source>
          <year>2005</year>
          <volume>53</volume>
          <fpage>931</fpage>
          <lpage>938</lpage>
          <pub-id pub-id-type="pmid">16342107</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b13-cia-4-391">
        <label>13</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCarty</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>O&#x2019;Duffy</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hunter</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome</article-title>
          <source>JAMA</source>
          <year>1985</year>
          <volume>254</volume>
          <fpage>2763</fpage>
          <lpage>2767</lpage>
          <pub-id pub-id-type="pmid">4057484</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b14-cia-4-391">
        <label>14</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olive</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>del Blanco</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pons</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Vaquero</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tena</surname>
              <given-names>X</given-names>
            </name>
          </person-group>
          <article-title>The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE</article-title>
          <source>J Rheumatol</source>
          <year>1997</year>
          <volume>24</volume>
          <fpage>333</fpage>
          <lpage>336</lpage>
          <pub-id pub-id-type="pmid">9034993</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b15-cia-4-391">
        <label>15</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pulsatelli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dolzani</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Silvestri</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>562</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="pmid">17181926</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b16-cia-4-391">
        <label>16</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Origuchi</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tamai</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>RS3PE syndrome presenting as vascular endothelial growth factor associated disorder</article-title>
          <source>Ann Rheum Dis</source>
          <year>2005</year>
          <volume>64</volume>
          <fpage>1653</fpage>
          <lpage>1655</lpage>
          <pub-id pub-id-type="pmid">16227418</pub-id>
        </mixed-citation>
      </ref>
      <ref id="b17-cia-4-391">
        <label>17</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Triplett</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Pfister</surname>
              <given-names>AK</given-names>
            </name>
          </person-group>
          <article-title>The clinical entity of remitting seronegative synovitis with pitting edema (RS3PE syndrome)</article-title>
          <source>W V Med J</source>
          <year>2001</year>
          <volume>97</volume>
          <fpage>302</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="pmid">11828677</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="f1-cia-4-391" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Gallium-67 scintigraphic findings of patients with polymyalgia rheumatica (<bold>P</bold>), pseudogout <bold>A</bold>), remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome <bold>B</bold>), and post-infectious polyarthritis <bold>C</bold>). <bold>A</bold>&#x2013;<bold>C</bold> corresponds to case <bold>A</bold>&#x2013;<bold>C</bold> in <xref ref-type="table" rid="t1-cia-4-391">Table 1</xref>, respectively. Arrows indicate a gallium uptake. Dotted arrows indicate a gallium uptake in metacarpophalangeal joints in a patient in RS3PE syndrome.</p>
      </caption>
      <graphic xlink:href="cia-4-391f1"/>
    </fig>
    <fig id="f2-cia-4-391" position="float">
      <label>Figure 2</label>
      <caption>
        <p>The radiographs of the patient with pseudogout demonstrated chondrocalcinosis (arrows) on the wrist <bold>A</bold>), knee <bold>B</bold>), and hip <bold>C</bold>).</p>
      </caption>
      <graphic xlink:href="cia-4-391f2"/>
    </fig>
    <table-wrap id="t1-cia-4-391" position="float">
      <label>Table 1</label>
      <caption>
        <p>Age, serum CRP, MMP-3, VEGF levels before and after the treatment in patients with PMR, pseudogout, RS3PE syndrome, and post-infectious polyarthritis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Case</th>
            <th align="left" rowspan="1" colspan="1">Diagnosis</th>
            <th align="left" rowspan="1" colspan="1">Age</th>
            <th align="left" rowspan="1" colspan="1"/>
            <th align="left" rowspan="1" colspan="1">CRP (mg/dl)</th>
            <th align="left" rowspan="1" colspan="1">MMP-3 (ng/ml)</th>
            <th align="left" rowspan="1" colspan="1">VEGF (pg/ml)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">PMR (n = 7)</td>
            <td align="left" rowspan="1" colspan="1">78.1 &#xB1; 8.2</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">11.4 &#xB1; 4.8</td>
            <td align="left" rowspan="1" colspan="1">189.0 &#xB1; 91.4</td>
            <td align="left" rowspan="1" colspan="1">1,114.2 &#xB1; 297.4</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After</td>
            <td align="left" rowspan="1" colspan="1">1.5 &#xB1; 1.0<xref ref-type="table-fn" rid="tfn2-cia-4-391">*</xref></td>
            <td align="left" rowspan="1" colspan="1">286.9 &#xB1; 204.0</td>
            <td align="left" rowspan="1" colspan="1">565.1 &#xB1; 182.3<xref ref-type="table-fn" rid="tfn2-cia-4-391">*</xref></td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">A</td>
            <td align="left" rowspan="1" colspan="1">Pseudogout</td>
            <td align="left" rowspan="1" colspan="1">83</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">24.3</td>
            <td align="left" rowspan="1" colspan="1">252.0</td>
            <td align="left" rowspan="1" colspan="1">1,190</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After</td>
            <td align="left" rowspan="1" colspan="1">1.2</td>
            <td align="left" rowspan="1" colspan="1">117.0</td>
            <td align="left" rowspan="1" colspan="1">894</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">B</td>
            <td align="left" rowspan="1" colspan="1">RS3PE syndrome</td>
            <td align="left" rowspan="1" colspan="1">65</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">17.8</td>
            <td align="left" rowspan="1" colspan="1">729.0</td>
            <td align="left" rowspan="1" colspan="1">1,650</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After</td>
            <td align="left" rowspan="1" colspan="1">8.5</td>
            <td align="left" rowspan="1" colspan="1">328.0</td>
            <td align="left" rowspan="1" colspan="1">1070</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">C</td>
            <td align="left" rowspan="1" colspan="1">Post-infectious polyarthritis</td>
            <td align="left" rowspan="1" colspan="1">89</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">12.1</td>
            <td align="left" rowspan="1" colspan="1">238.0</td>
            <td align="left" rowspan="1" colspan="1">805</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After</td>
            <td align="left" rowspan="1" colspan="1">1.3</td>
            <td align="left" rowspan="1" colspan="1">70.1</td>
            <td align="left" rowspan="1" colspan="1">450</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn1-cia-4-391">
          <p><bold>Notes:</bold> Cases A&#x2013;C corresponds to A&#x2013;C in <xref ref-type="fig" rid="f1-cia-4-391">Figure 1</xref>, respectively. Values in PMR patients indicate mean &#xB1; SD.</p>
        </fn>
        <fn id="tfn2-cia-4-391">
          <label>*</label>
          <p><italic>P</italic> &lt; 0.05 vs values before the treatment by Wilcoxon&#x2019;s signed rank test. Normal range of CRP, MMP-3, and VEGF levels is &lt;0.3 mg/dl, &lt;115 ng/ml, and 17.3&#x2013;59.7 pg/ml, respectively.</p>
        </fn>
        <fn id="tfn3-cia-4-391">
          <p><bold>Abbreviations:</bold> CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; PMR, polymyalgia rheumatica; RS3PE, remitting seronegative symmetrical synovitis with pitting edema.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t2-cia-4-391" position="float">
      <label>Table 2</label>
      <caption>
        <p>Changes in serum CRP levels after one week&#x2019;s treatment using NSAIDs in patients with PMR, pseudogout, RS3PE syndrome, and post-infectious polyarthritis</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Case</th>
            <th align="left" rowspan="1" colspan="1">Diagnosis</th>
            <th align="left" rowspan="1" colspan="1"/>
            <th align="left" rowspan="1" colspan="1">CRP (mg/dl)</th>
            <th align="left" rowspan="1" colspan="1">%Changes of serum CRP levels</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">PMR (n = 7)</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">10.4 &#xB1; 4.4</td>
            <td align="left" rowspan="1" colspan="1">&#x2212;7.2%</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After one week</td>
            <td align="left" rowspan="1" colspan="1">9.1 &#xB1; 3.4<xref ref-type="table-fn" rid="tfn5-cia-4-391">#</xref></td>
            <td align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">A</td>
            <td align="left" rowspan="1" colspan="1">Pseudogout</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">24.3</td>
            <td align="left" rowspan="1" colspan="1">&#x2212;95.1%</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After one week</td>
            <td align="left" rowspan="1" colspan="1">1.2</td>
            <td align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">B</td>
            <td align="left" rowspan="1" colspan="1">RS3PE syndrome</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">20.8</td>
            <td align="left" rowspan="1" colspan="1">&#x2212;22.1%</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After one week</td>
            <td align="left" rowspan="1" colspan="1">16.2</td>
            <td align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">C</td>
            <td align="left" rowspan="1" colspan="1">Post-infectious polyarthritis</td>
            <td align="left" rowspan="1" colspan="1">Before</td>
            <td align="left" rowspan="1" colspan="1">12.1</td>
            <td align="left" rowspan="1" colspan="1">&#x2212;89.3%</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1">After one week</td>
            <td align="left" rowspan="1" colspan="1">1.3</td>
            <td align="left" rowspan="1" colspan="1"/>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn4-cia-4-391">
          <p><bold>Notes:</bold> Case A&#x2013;C corresponds to A&#x2013;C in <xref ref-type="fig" rid="f1-cia-4-391">Figure 1</xref>, respectively. Values in PMR patients indicate mean &#xB1; SD.</p>
        </fn>
        <fn id="tfn5-cia-4-391">
          <label>#</label>
          <p>Indicates no significant differences vs values before treatment by Wilcoxon&#x2019;s signed rank test.</p>
        </fn>
        <fn id="tfn6-cia-4-391">
          <p><bold>Abbreviations:</bold> CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; PMR, polymya rheumatica; RS3PE, remitting seronegative symmetrical synovitis with pitting edema.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="t3-cia-4-391" position="float">
      <label>Table 3</label>
      <caption>
        <p>Clinical and biochemical characteristics for polymyalgia rheumatic</p>
      </caption>
      <table frame="hsides" rules="none">
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">Age &#x2265; 50 years</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Elevated serum CRP, MMP-3, and VEGF levels</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Symmetrical gallium-67 uptake in shoulders and/or pelvic girdle</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">A bad response to NSAIDs</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">A rapid response to steroid</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">No abnormalities in the radiographs of joints</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="tfn7-cia-4-391">
          <p><bold>Abbreviations:</bold> CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; NSAIDs, nonsteroidal anti-inflammatory drugs.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>
</pmc-articleset>
